Earning Analysis
Welcome to our in-depth analysis of MDxHealth SA(MDXH) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of MDxHealth SA earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-12 | After Hours | -0.12 | -0.16 | -33.33 | 27.92M | 27.42M | -1.77 | -3.64 | -22.09 |
| FY2028Q4 | 2025-05-14 | After Hours | -0.13 | -0.19 | -46.15 | 24.78M | 24.22M | -2.28 | +6.74 | +21.35 |
| FY2028Q3 | 2025-02-26 | After Hours | -0.20 | -0.14 | +30.00 | 23.16M | 24.69M | +6.61 | +1.64 | -14.75 |
| FY2028Q1 | 2024-08-21 | After Hours | -0.26 | -0.42 | -61.54 | 21.09M | 22.20M | +5.30 | -12.23 | -12.54 |
| FY2027Q4 | 2024-05-01 | - | -0.30 | -0.31 | -3.33 | 17.82M | 19.83M | +11.32 | +6.80 | +24.40 |
| FY2027Q3 | 2024-03-06 | - | - | -0.39 | - | 18.93M | 19.39M | +2.42 | -1.32 | -31.22 |
| FY2027Q2 | 2023-11-08 | - | -0.31 | -0.40 | -29.03 | 18.29M | 19.35M | +5.82 | +1.97 | +1.64 |
| FY2027Q1 | 2023-08-23 | - | -0.32 | -0.30 | +6.25 | 15.59M | 16.77M | +7.55 | +3.08 | -15.69 |
| - | 2023-05-15 | - | -0.40 | -0.05 | +87.50 | - | - | - | -0.81 | +3.50 |
| - | 2023-03-08 | - | -0.75 | -1.10 | -46.67 | - | - | - | -1.34 | -26.47 |
MDXH Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, MDxHealth SA reported performance for FY2025Q3, announced on 2025-11-12. The company achieved an EPS of -0.16, compared to analyst estimates of -0.12 by -33.33% . Revenue for the quarter reached 27.42M compared to expectations of 27.92M by -1.77% .
The stock price reacted with a -3.64% one-day change and a -22.09% five-day change following the earnings release. These movements reflect market reaction in MDxHealth SA growth trajectory and strategic initiatives.
MDXH Earnings Forecast
Looking ahead, MDxHealth SA(MDXH) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -1.26%, while EPS estimates have been Revise Upward by 14.29%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -0.62% . These revisions correlate with a 3.12% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in MDxHealth SA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between MDXH's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-1.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+14.29%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-0.62%
In Past 3 Month
Stock Price
Go Up
+3.12%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:108.97M
--
EPS Estimate-Annual FY 2025:-0.62
—
Stock Price3.64
MDXH Revenue and EPS Performance: A Historical Perspective
MDxHealth SA revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-12,After Hours):
EPS: -0.16 (Actual) vs.-0.12 (Estimate) (-33.33%)
Revenue: 27.42M (Actual) vs. 27.92M (Estimate) (-1.77%)
Price Reaction: -3.64%(1-Day), -22.09%(5-Day)
FY2028Q4 (2025-05-14,After Hours):
EPS: -0.19 (Actual) vs.-0.13 (Estimate) (-46.15%)
Revenue: 24.22M (Actual) vs. 24.78M (Estimate) (-2.28%)
Price Reaction: 6.74%(1-Day), 21.35%(5-Day)
FY2028Q3 (2025-02-26,After Hours):
EPS: -0.14 (Actual) vs.-0.20 (Estimate) (30.00%)
Revenue: 24.69M (Actual) vs. 23.16M (Estimate) (6.61%)
Price Reaction: 1.64%(1-Day), -14.75%(5-Day)
Earnings Reaction
The chart below shows how MDXH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MDXH sees a -5.26% change in stock price 10 days leading up to the earnings, and a -8.66% change 10 days following the report. On the earnings day itself, the stock moves by -0.96%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -3.64% on the day following the earnings release and then changed by -10.92% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
MDxHealth SA (MDXH) Q3 2025 Earnings Call Summary
Positive
2025-11-12
The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.
MDxHealth SA (MDXH) Q1 2025 Earnings Call Summary
Neutral
2025-05-14
The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.
MDxHealth SA (MDXH) Q4 2024 Earnings Call Summary
Positive
2025-02-26
The earnings call summary shows strong revenue growth and improved financial metrics, with optimistic guidance and raised revenue projections for 2024 and beyond. Despite some risks and uncertainties, the Q&A reveals confidence in the company's strategic direction and market position. The absence of a shareholder return plan is a minor drawback, but overall, the positive financial performance and guidance outweigh potential concerns, suggesting a positive stock price movement.
MDxHealth SA (MDXH) Q3 2024 Earnings Call Summary
Positive
2024-11-08
The earnings call summary indicates strong financial performance with a 32% revenue growth and raised guidance. Despite a decline in gross margins and increased operating loss, the company has a solid cash position post-equity financing. The Q&A highlighted management's confidence in meeting guidance and sustainable growth through urology adoption and test expansion. Analysts' questions reflected interest in growth levers and market dynamics, with no major concerns raised. The overall sentiment is positive, with potential stock price increase driven by raised guidance and sustainable growth outlook.
MDxHealth SA (MDXH) Q2 2024 Earnings Call Summary
Positive
2024-08-22
MDxHealth's earnings call showed strong revenue growth, increased guidance, and improved gross margins. The Q&A highlighted sustainable growth and room for ASP improvements. Despite potential risks like regulatory issues and competition, the positive financial performance and strategic initiatives, such as the integration of new tests and market positioning, suggest a positive stock price reaction. The absence of a shareholder return plan is a minor drawback, but the overall sentiment is positive.
People Also Watch
FAQ
What were the key highlights of MDXH’s latest earnings report for FY2025Q3?
How did MDXH’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for MDXH for undefined?
How does MDXH’s stock price correlate with earnings forecast revisions?
What should investors expect from MDXH’s next earnings report?